Blood cancer Archives

Podcast 1 Sep 2023

Beyond Biotech podcast 61 – Blood Cancer Awareness Month

On this week’s podcast, to recognize Blood Cancer Awareness Month, we have a conversation with Affimed's CMO, Andreas Harstrick, to talk about blood cancers, and what Affimed is doing to…

September 1, 2023 - 2 minutesmins - By Jim Cornall

In Depth 26 Jul 2023

Antibody drug conjugates: BiVictriX drives a new era in cancer medicine

The first-ever antibody-drug conjugate (ADC) to be approved, gemtuzumab ozogamicin, raised hope for a new class of drugs to treat cancer. But the drug was then withdrawn following a black…

July 26, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 9 Jun 2023

Chronic myeloid leukemia: Novartis survey signals need for better patient-physician communication

Only 19% to 26% of patients with chronic myeloid leukemia (CML) discuss treatment decisions with their physician, a survey by Swiss-based pharmaceutical Novartis has revealed. The Survey of Unmet Needs…

June 9, 2023 - 4 minutesmins - By Roohi Mariam Peter

News and Trends 10 May 2023

Scientists create first CRISPR-based drug candidate targeting the microbiome

A new CRISPR-based drug candidate targeting E. coli in the gut microbiome is in phase 1 clinical trials. According to a new paper published in Nature Biotechnology, it may improve…

May 10, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

New promising targeted drug for a rare leukemia

Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone. Venetoclax is a new targeted therapy option…

February 23, 2023 - 3 minutesmins - By Jim Cornall

morphosys multiple myeloma immunooncology mor202

News and Trends 7 Dec 2015

Best-in-Class Label for Blood Cancer Trial by Billion Euro Biotech

Latest results of MorphoSys candidate for Multiple Myeloma show that it was Celgene's loss when it abandoned the phase I/IIa trial partnership on blood cancer. Announced at the American Society…

December 7, 2015 - 3 minutesmins - By Dani Bancroft

msd cancer research uk monash crt merck australia

News and Trends 1 Feb 2016

New Discovery unites Australia, Germany and UK Against Blood Cancers

Cancer Research UK has teamed up with MSD (Merck) and the Wellcome Trust to co-develop some Inhibitors for both Cancerous and Non-cancerous blood disorders from the Australian Academia-Biotech Network. The Australian…

February 1, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 28 May 2018

Genmab and Janssen Suffer Combination Therapy Setback

Janssen will discontinue a Phase I study testing Danish biotech Genmab's blood cancer blockbuster daratumumab combined with a candidate checkpoint inhibitor in patients with multiple myeloma. Janssen, which obtained the…

May 28, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 17 Nov 2017

Welcome to the Blockbuster Club, Genmab!

Genmab has achieved $1B sales in the US of its blood cancer drug, Darzalex, setting a great example for other European biotechs to follow. Genmab has officially joined the elite of…

November 17, 2017 - 3 minutesmins - By Alex Dale

merck msd cancer immunoncology complix alphabody

News and Trends 7 Jan 2016

Alphabody Platform for Cancer Draws in €260M Discovery Deal with MSD

Complix is a Belgian Immuno-Oncology Biotech with a proprietary Alphabody platform, which has now attracted a €260M strategic drug discovery collaboration with Merck Sharp & Dohme (MSD). Under the terms…

January 7, 2016 - 2 minutesmins - By Dani Bancroft

cancer biotech killers deadliest oncology therapies immunooncology

News and Trends 19 Jan 2016

Top 8 Deadliest Cancers and their Potential Cures

With more than 200 types of cancer, the possibility of developing a Universal Cure is in reality, a myth. However, the fight against the World's Deadliest Cancers is far from…

January 19, 2016 - 7 minutesmins - By Dani Bancroft

kesios myeloma imperial innovations london

News and Trends 2 Dec 2015

An Imperial College Based Start-Up Has Raised €27M in Series A for a Blood Cancer Drug

Kesios is a start-up Biotech based in London (UK) which has raised over €27M in a Series A funding round for its pipeline targeting the fight against multiple myeloma. A…

December 2, 2015 - 3 minutesmins - By Dani Bancroft

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with world-leading academics working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering